Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aquestive Therapeutics Inc

AQST
Current price
2.68 USD -0.08 USD (-2.90%)
Last closed 2.73 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 243 983 168 USD
Yield for 12 month +30.73 %
1Y
3Y
5Y
10Y
15Y
AQST
21.11.2021 - 28.11.2021

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. Address: 30 Technology Drive, Warren, NJ, United States, 07059

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

8.61 USD

P/E ratio

Dividend Yield

Current Year

+50 583 000 USD

Last Year

+47 680 000 USD

Current Quarter

+12 053 000 USD

Last Quarter

+13 206 000 USD

Current Year

+29 968 000 USD

Last Year

+28 294 000 USD

Current Quarter

+7 664 000 USD

Last Quarter

+8 527 000 USD

Key Figures AQST

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -18 200 000 USD
Operating Margin TTM -74.31 %
PE Ratio
Return On Assets TTM -12.74 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 8.61 USD
Revenue TTM 51 502 000 USD
Book Value -0.4 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 8.3 %
Dividend Yield
Gross Profit TTM 28 294 000 USD
Earnings per share -0.45 USD
Diluted Eps TTM -0.45 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -55.85 %

Dividend Analytics AQST

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AQST

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AQST

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 7.1234
Price Sales TTM 6.9544
Enterprise Value EBITDA 304.8407
Price Book MRQ

Financials AQST

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AQST

For 52 weeks

1.25 USD 6.23 USD
50 Day MA 3.36 USD
Shares Short Prior Month 6 183 555
200 Day MA 2.7 USD
Short Ratio 2.6
Shares Short 6 700 819
Short Percent 8.14 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics